An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
暂无分享,去创建一个
H. Inoue | T. Yokomizo | T. Okuno | I. Higashimoto | Masaki Watanabe | K. Machida | M. Shirato | Shingo Kubota
[1] P. Poole,et al. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.
[2] Y. Nakanishi,et al. Cigarette smoke impairs phagocytosis of apoptotic neutrophils by alveolar macrophages via inhibition of the histone deacetylase/Rac/CD9 pathways. , 2013, International immunology.
[3] T. Yokomizo,et al. Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand[S] , 2013, Journal of Lipid Research.
[4] M. Cazzola,et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. , 2013, The Lancet. Respiratory medicine.
[5] H. Watz,et al. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. , 2013, Pulmonary pharmacology & therapeutics.
[6] K. Rabe,et al. Phosphodiesterase-4 inhibitor therapy for lung diseases. , 2013, American journal of respiratory and critical care medicine.
[7] M. Kubo,et al. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] I. Hishinuma,et al. Antipruritic Effect of the Topical Phosphodiesterase 4 Inhibitor E6005 Ameliorates Skin Lesions in a Mouse Atopic Dermatitis Model , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[9] A. Condliffe,et al. The neutrophil in chronic obstructive pulmonary disease. , 2013, American journal of respiratory cell and molecular biology.
[10] P. Davis,et al. Higher versus lower oxygen concentrations titrated to target oxygen saturations during resuscitation of preterm infants at birth , 2012 .
[11] Domenico Spina,et al. Selective PDE inhibitors as novel treatments for respiratory diseases. , 2012, Current opinion in pharmacology.
[12] S. Rennard,et al. PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease , 2012, Clinical pharmacology and therapeutics.
[13] K. Austen,et al. Cysteinyl Leukotrienes Impair Hypoxic Pulmonary Vasoconstriction in Endotoxemic Mice , 2011, Anesthesiology.
[14] Richard Graham Knowles,et al. GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization , 2011, Journal of Pharmacology and Experimental Therapeutics.
[15] Richard Graham Knowles,et al. In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor , 2011, Journal of Pharmacology and Experimental Therapeutics.
[16] N. Suttorp,et al. Innate immune recognition in infectious and noninfectious diseases of the lung. , 2010, American journal of respiratory and critical care medicine.
[17] J. Vestbo,et al. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD , 2009, European Respiratory Journal.
[18] D. Aronoff,et al. Cyclic AMP: master regulator of innate immune cell function. , 2008, American journal of respiratory cell and molecular biology.
[19] N. Hoefgen,et al. In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration , 2003, Journal of Pharmacology and Experimental Therapeutics.
[20] S. Jin,et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.
[21] C. Chan,et al. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway , 2001, Neuropharmacology.
[22] A. Sapirstein,et al. Attenuation of Hypoxic Pulmonary Vasoconstriction by Endotoxemia Requires 5-Lipoxygenase in Mice , 2001, Circulation research.
[23] P. Ward,et al. Expression of lung vascular and airway ICAM-1 after exposure to bacterial lipopolysaccharide. , 1997, American journal of respiratory cell and molecular biology.
[24] T. Standiford,et al. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. , 1995, Journal of immunology.
[25] P. Ward,et al. Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. , 1995, Journal of immunology.
[26] J. Paulauskis,et al. Functional characterization of rat chemokine macrophage inflammatory protein-2 , 1995, Inflammation.
[27] J. Paulauskis,et al. Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation. , 1992, The American journal of pathology.
[28] N. Voelkel,et al. Endotoxin-induced lung injury in rats: role of eicosanoids. , 1989, Journal of applied physiology.
[29] H. Inoue,et al. Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. , 2003, American journal of respiratory and critical care medicine.
[30] A. Ishizaka,et al. Effects of ONO-1078, a peptide leukotriene antagonist, on endotoxin-induced acute lung injury. , 1994, American journal of respiratory and critical care medicine.